文献速递基础与转化研究临床试验与 GCP

抗体精细特异性与非洲幼儿RTS,S疫苗疟疾保护相关:IIb期随机对照试验事后分析

Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial.
PubMed 文献 · PLoS Med · 2026-05-14

该研究对RTS,S/AS01疟疾疫苗IIb期试验中1-4岁非洲儿童(n=735)进行事后分析,评估疫苗诱导抗体对CSP六个表位的特异性。发现对NANP2和J1表位高IgG应答的儿童临床疟疾风险显著降低(aHR分别为0.838和0.718),且与更高的Fc介导功能活性相关。

要点

  • NANP2和J1表位高IgG应答与临床疟疾风险降低显著相关。
  • 上述抗体应答与更高的Fc介导功能活性相关。
  • 结果需在其它RTS,S和R21队列中进一步验证。

核心结论

  • RTS,S疫苗诱导的针对NANP2和J1表位的IgG应答与幼儿临床疟疾保护相关,为下一代疫苗开发提供新线索。

研究设计与样本

  • RTS,S/AS01 IIb期随机对照试验的事后分析,纳入1-4岁儿童n=735,并结合临床前小鼠疫苗研究和CSP特异性单克隆抗体评估。

主要发现

  • 高IgG应答至NANP2的儿童临床疟疾风险显著降低(aHR: 0.838 (95% CI [0.716, 0.981]; p = 0.028))。
  • 高IgG应答至J1的儿童临床疟疾风险显著降低(aHR: 0.718 (95% CI [0.611, 0.844]; p < 0.001))。
  • NANP2和J1高应答与更高的抗体Fc介导功能活性相关。
  • 小鼠免疫NANP重复区可产生与N端表位交叉反应的IgG,单一CSP特异性mAb可交叉反应多个表位。

临床怎么用

  • NANP2和J1抗体应答可作为RTS,S疫苗免疫保护的相关标志物,用于疫苗效果评估。

局限性

  • NANP2和J1作为保护相关物仅在一个IIb期队列中评估,需在其它RTS,S和R21队列中进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The RTS,S/AS01 malaria vaccine was recently approved for implementation in children, but only provides modest and short-lived efficacy against malaria. RTS,S targets a portion of the Plasmodium falciparum (Pf) circumsporozoite protein (CSP), comprising the central NANP-repeat region and C-terminal domain. Mechanisms of immunity and correlates of protection for the RTS,S vaccine are not well defined, hindering progress towards generating highly effective CSP-based vaccines. METHODS AND FINDINGS: We investigated epitope specificity and cross-reactivity of vaccine-induced antibodies to six peptides representing CSP epitopes in the N-terminal and central NANP-repeat region. We evaluated antibody reactivity in preclinical mouse vaccine studies, among CSP-specific monoclonal antibodies (mAbs), and in a large RTS,S phase IIb clinical trial in young children 1-4 years old (n = 735). The preclinical mouse vaccine studies and CSP-specific mAbs were used to initially evaluate IgG responses to the six peptides. Mice immunised with the central NANP-repeat region had IgG with cross-reactivity to an epitope in the N-terminal region. Additionally, we demonstrated that a single CSP-specific mAb could display cross-reactivity to several CSP epitopes. Through post hoc quantification and analysis of antibody responses in the RTS,S phase IIb clinical trial, we found that a subset of children generated IgG with specificity for a short NANP-repeat epitope (NANP2; amino acid sequence: NANPNANP) and cross-reactivity to an N-terminal epitope (J1; amino acid sequence: KQPADGNPDPNANPN). Notably, children with high IgG responses to NANP2 and J1 had a significantly reduced risk of clinical malaria, compared to children with low responses (IgG to NANP2 (aHR: 0.838 (95% CI [0.716, 0.981]; p = 0.028)) and J1 (aHR: 0.718 (95% CI [0.611, 0.844]; p < 0.001)), and these responses were also associated with higher antibody Fc-mediated functional activities. We have evaluated NANP2 and J1 as immunological correlates of protection in one phase IIb cohort, additional studies in other RTS,S and R21 cohorts will be important to further confirm our findings. CONCLUSIONS: These findings reveal promising new correlates of protection for RTS,S and new insights to inform the development of next-generation malaria vaccines.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Hysa A, Opi DH, Waterhouse J, et al. Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial. PLoS Med. 2026. PMID: 42133737. doi:10.1371/journal.pmed.1004877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。